Last reviewed · How we verify
placebo alone
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, independent of any active pharmacological mechanism.
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, independent of any active pharmacological mechanism. Used for Control comparator in clinical trials across multiple therapeutic areas.
At a glance
| Generic name | placebo alone |
|---|---|
| Sponsor | University Magna Graecia |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo works by activating the patient's expectation of benefit, which can trigger real physiological changes including endogenous neurotransmitter release, immune modulation, and pain pathway alterations. This effect is particularly pronounced in conditions with subjective symptom components such as pain, nausea, and fatigue. The placebo response is a well-documented phenomenon in clinical medicine and is used as a control comparator in randomized trials.
Approved indications
- Control comparator in clinical trials across multiple therapeutic areas
Common side effects
- Nocebo effects (adverse events attributed to placebo expectation)
Key clinical trials
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair (NA)
- Effect of Kinesio Taping Application in Addition to Pilates Exercises on Core Muscle Thickness, Cognition and Mental Fatigue in Individuals With Non-specific Low Back Pain (NA)
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo alone CI brief — competitive landscape report
- placebo alone updates RSS · CI watch RSS
- University Magna Graecia portfolio CI